Rome blocks the export of AstraZeneca vaccines, a first in the EU – Julian Stratenschulte / AP / SIPA
A first in the European Union. Rome has blocked the export to Australia of doses of AstraZeneca’s anti-Covid vaccine produced on European soil. This is the first application of a control mechanism put in place by Brussels, the Italian government announced on Thursday. Italy communicated its decision on February 26 to the European Commission, which raised no objections.
The Foreign Ministry said in a statement that this export refusal related to 250,700 doses from the Swedish-British laboratory. Italy justified this by “the persistent shortage of vaccines and delays in supply from AstraZeneca” in the EU and Italy, the “large quantity” of doses concerned and the fact that Australia is considered a “non-vulnerable” country by the EU mechanism.
Only a third of the 120 million doses delivered
– Advertisement –
AstraZeneca has been heavily criticized by European governments after announcing in January that it could deliver only a third of the 120 million doses it had initially promised to the 27 EU member states in the first quarter, due to manufacturing difficulties in the first quarter. a Belgian factory. The argument did not convince Brussels, which recalled that three other factories were mentioned in the contract signed with the EU.
The Australian Ministry of Foreign Affairs on Friday minimized the impact of Italy’s decision on its vaccination plan. The delivery of doses of AstraZeneca that the Italian government has blocked “was not included in our distribution plan for the next few weeks,” said a spokesperson for the ministry. “It’s just one shipment from one country,” he said.
Safeguards to exports
Australia, which approved the AstraZeneca vaccine in mid-February, has already received a delivery of 300,000 doses of this vaccine, and the first are to be injected this Friday to healthcare workers in the south of the country. These 300,000 doses, coming in addition to doses of the Pfizer vaccine, should make it possible to hold out until the pace of Australian production of AstraZeneca is increased. About 50 million doses need to be produced locally.
Although denying itself to target AstraZeneca specifically, the European Commission has been imposing safeguards on exports of anti-Covid vaccines produced in the EU since the end of January, in order to keep control of the doses intended for the Twenty-Seven.
Autonomous state control at customs
This is the first time that a member state has blocked an export through this mechanism, said a European source. The system provides that the States themselves exercise this control via their national customs: each State examines the applications for export authorization for vaccines manufactured on its territory, before seeking the opinion of the Commission, to which it must comply. conform.
The Commission “maintains a table of requests for the export of anti-Covid vaccines and the corresponding commitments” from laboratories under the pre-order agreements made by the EU, and it is on this basis that it has approved the Italian decision, according to another European source. AstraZeneca, which manufactures its anti-Covid vaccine at sites in Belgium and the Netherlands, has a bottling and packaging plant in Italy in Anagni, near Rome.
Only 1.51 million Italians vaccinated
As in many Member States, voices were raised in Italy to criticize the slowness of the vaccination campaign, launched with fanfare at the end of December but which quickly encountered delays in deliveries.
At this stage, 1.51 million Italians have been vaccinated, mainly health workers and the elderly, and 4.84 million doses have been administered, for a total population of some 60 million.
I hope you are in health and well.
I offer you important instructions regarding this article
- The article has been translated based on the content of the source link below these instructions
If there is any problem related to the content, copyright, correctness of the information contained in this article, or If there are errors in the language, please leave a report below the article. or contact us via email [email protected]. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
- We only want readers to access information quickly and easily using other multilingual content, rather than information only available in a specific language.
- We always respect the copyright of the author’s content and always include the original link of the source article, and if the author does not agree, leave the report below the article, the article will be edited or deleted at the author’s request. Thank you so much! Warm greetings!